Margarida Azevedo, MSc,  —

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.

Articles by Margarida Azevedo

Dosing Completed in Phase 1 Study of GTP-004 for Myasthenia Gravis Treatment Side Effects

Dosing has been completed in the Phase 1 clinical trial of GTP-004, a new candidate for the treatment of symptoms associated with myasthenia gravis (MG), including gastrointestinal side effects of pyridostigmine, the investigational therapy’s developer, GT Biopharma, announced. Preliminary results suggest that GTP-004 enables the safe and well-tolerated administration…

Alexion Receives Extended Patent in Japan for Soliris (Eculizumab)

The Japanese Patent Office (JPO) has issued a new patent for the composition of eculizumab, marketed as Soliris by Alexion Pharmaceuticals, and its pharmaceutical formulations until 2027. Alexion is currently pursuing a patent for additional indications of Soliris, including for the treatment of anti-acetylcholine receptor (AchR) antibody-positive generalized…

argenx Doses First Subject in Study Evaluating Subcutaneous ARGX-113 for Autoimmune Diseases

The first participant has been dosed in a Phase 1 clinical trial evaluating  argenx‘s subcutaneous formulation of ARGX-113 in healthy volunteers. ARGX-113 is an investigational antibody designed for the treatment of patients with severe autoimmune diseases associated with high levels of harmful immunoglobulin G (IgG) antibodies, such as myasthenia gravis (MG).